查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611313

呼吸道感染疾病診斷市場：按測試、疾病和最終用戶分類 - 全球預測 2025-2030

Respiratory Infection Diagnostics Market by Test (Antigen Detection Assays, Direct Fluorescent Antibody Tests, Imaging Tests), Disease (Asthma, Chronic Obstructive Pulmonary Disease, Coronavirus Infections), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，呼吸道感染疾病診斷市場價值為769.4億美元，預計到2024年將達到823.5億美元，複合年成長率為7.15%，到2030年將達到1247.8億美元，預計將達到1000萬美元。

調查方法包括用於診斷流感、肺炎、結核病和 COVID-19 等疾病的工具和技術。其範圍包括使用聚合酵素鏈鎖反應(PCR)、快速抗原檢測和血清學等技術來識別致病病原體（病毒、細菌、真菌）。感染疾病感染疾病的需求，這構成了重大的公共衛生問題，特別是在人口稠密和免疫力的地區。研究應用多種多樣，包括臨床環境、研究機構和家庭檢測套組，凸顯了市場廣泛的最終用途。影響成長的主要因素包括人們對快速診斷的認知和需求的提高、技術進步以及感染疾病率的上升。數位健康技術和人工智慧的最新進展透過實現更準確的診斷和促進個人化醫療方法為公司提供了潛在的機會。鼓勵公司投資可攜式快速測試解決方案、數位整合和自動化，以滿足不斷成長的需求。然而，這個市場面臨一些限制，例如與先進診斷相關的高成本、監管核准的挑戰以及對高技能人員的需求。這些因素可能會限制市場滲透率，特別是在新興市場。公司必須透過專注於具有成本效益且可靠的解決方案來克服這些挑戰。此外，還需要提高診斷的準確性和速度，並且需要開發整合的即時測試設備和使用機器學習演算法來更好地解釋資料等創新。該市場競爭激烈、發展迅速且注重創新，為能夠策略性地解決現有障礙的公司創造了重大機會。由於市場的動態性，有必要跟上當前趨勢和技術進步，以保持競爭力並有效滿足世界醫療保健需求。

主要市場統計
基準年[2023] 769.4億美元
預計年份 [2024] 823.5億美元
預測年份 [2030] 1247.8億美元
複合年成長率（%） 7.15%

市場動態：快速發展的呼吸道感染疾病診斷市場的關鍵市場洞察

供需的動態交互作用正在改變呼吸道感染疾病診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性阻塞性肺病(COPD) 增加
    • 醫療基礎設施的發展和診斷方法的增加
    • 政府對感染疾病診斷的經費快速增加
  • 市場限制因素
    • 由於診斷和測試成本上升而導致報銷限制
  • 市場機會
    • 次世代定序儀平台可用於診斷呼吸道感染疾病
    • 擴大研發活動
  • 市場挑戰
    • 嚴格的監管約束

波特五力：駕馭呼吸道感染疾病診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解呼吸道感染疾病診斷市場的外部影響

外部宏觀環境因素在塑造呼吸道感染疾病診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解呼吸道感染疾病診斷市場的競爭狀況

呼吸道感染疾病診斷市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣呼吸道感染疾病診斷市場供應商的績效評估

FPNV定位矩陣是評估呼吸道感染疾病診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪呼吸道感染疾病診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對呼吸道感染疾病診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性阻塞性肺病（COPD）發生率上升
      • 平衡加強醫療基礎設施和診斷程序的可用性
      • 政府對感染疾病診斷的經費快速增加
    • 抑制因素
      • 高昂的診斷和測試成本限制了報銷
    • 機會
      • 基於次世代定序的平台可用於診斷呼吸道感染疾病
      • 擴大研發活動
    • 任務
      • 嚴格的監管約束
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 呼吸道感染疾病診斷市場測試

  • 抗原檢測試驗
  • 直接螢光抗體檢測
  • 影像檢查
    • 電腦斷層掃描
    • X光
  • 體外診斷 (IVD) 測試
  • 核酸增幅檢查
  • 快速診斷測試

第7章呼吸道感染疾病診斷市場：依疾病分類

  • 氣喘
  • 慢性阻塞性肺病
  • 冠狀病毒感染疾病
  • 腸病毒
  • 流感
  • 肺癌
  • 肺炎
  • 結核
  • 百日咳

第8章呼吸道感染疾病診斷市場：依最終使用者分類

  • 臨床實驗室
  • 醫院

第9章北美和南美呼吸道感染疾病診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區呼吸道感染疾病診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲呼吸道感染疾病診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AccuBioTech Co. Ltd.
  • Atomo Diagnostics Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • BIORON Diagnostics GmbH
  • Cardinal Health Inc.
  • Chembio Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Merck KGaA
  • Meridian Bioscience Inc. by SD Biosensor
  • Quest Diagnostics Incorporated
  • Quidel Corporation
Product Code: MRR-02026C4C8612

The Respiratory Infection Diagnostics Market was valued at USD 76.94 billion in 2023, expected to reach USD 82.35 billion in 2024, and is projected to grow at a CAGR of 7.15%, to USD 124.78 billion by 2030.

The respiratory infection diagnostics market encompasses tools and methodologies used to diagnose diseases such as influenza, pneumonia, tuberculosis, and COVID-19, among others. The scope involves identifying causative pathogens-viruses, bacteria, and fungi-using technologies like polymerase chain reaction (PCR), rapid antigen tests, and serology. The necessity of respiratory infection diagnostics is underscored by the prevalence and spread of infections, which pose significant public health concerns, especially in densely populated and immunocompromised regions. Applications span clinical settings, research institutions, and home testing kits, highlighting the market's wide end-use spectrum. Key factors influencing growth include heightened awareness and demand for rapid diagnostics, technological advances, and rising incidences of infectious diseases. The recent advancement in digital health technology and artificial intelligence presents potential opportunities for businesses, enabling more precise diagnosis and facilitating personalized medicine approaches. Companies are recommended to invest in portable and rapid testing solutions, digital integration, and automation to meet the growing demand. However, the market faces limitations such as high costs associated with advanced diagnostics, regulatory approval challenges, and the need for highly skilled personnel. These factors can restrict market penetration, particularly in developing regions. Businesses must navigate these challenges by focusing on cost-effective yet reliable solutions. Additionally, there is an ongoing need for improved diagnostic accuracy and speed, representing viable areas for innovation, such as developing integrated point-of-care (POC) testing devices and leveraging machine learning algorithms for better data interpretation. The respiratory infection diagnostics market is competitive and rapidly evolving, with a strong focus on innovation, thereby presenting a robust opportunity for companies that can strategically address existing barriers. The market's dynamic nature requires staying abreast of current trends and technological advancements to remain competitive and meet global healthcare needs efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 76.94 billion
Estimated Year [2024] USD 82.35 billion
Forecast Year [2030] USD 124.78 billion
CAGR (%) 7.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Infection Diagnostics Market

The Respiratory Infection Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic obstructive pulmonary disease (COPD)
    • Increasing healthcare infrastructure coupled with the availability of diagnostic procedures
    • Rapid rise in government funding towards infectious disease diagnostics
  • Market Restraints
    • High cost of diagnosis and testing limited reimbursement scenarios
  • Market Opportunities
    • Availability of next-generation sequencing-based platform to diagnose respiratory tract infections
    • Expanding number of R&D activities
  • Market Challenges
    • Strict regulatory constraints

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Infection Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Infection Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Infection Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Infection Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Infection Diagnostics Market

A detailed market share analysis in the Respiratory Infection Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Infection Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Infection Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Infection Diagnostics Market

A strategic analysis of the Respiratory Infection Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Infection Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co. Ltd., Atomo Diagnostics Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, BIORON Diagnostics GmbH, Cardinal Health Inc., Chembio Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Merck KGaA, Meridian Bioscience Inc. by SD Biosensor, Quest Diagnostics Incorporated, and Quidel Corporation.

Market Segmentation & Coverage

This research report categorizes the Respiratory Infection Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Antigen Detection Assays, Direct Fluorescent Antibody Tests, Imaging Tests, In Vitro Diagnostics (IVD) Tests, Nucleic Acid Amplification Tests, and Rapid Diagnostic Tests. The Imaging Tests is further studied across CT- Scan and X-ray.
  • Based on Disease, market is studied across Asthma, Chronic Obstructive Pulmonary Disease, Coronavirus Infections, Enterovirus, Influenza diseases, Lung Cancer, Pneumonia, Tuberculosis, and Whooping Cough (Pertussis).
  • Based on End-User, market is studied across Clinical Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic obstructive pulmonary disease (COPD)
      • 5.1.1.2. Increasing healthcare infrastructure coupled with the availability of diagnostic procedures
      • 5.1.1.3. Rapid rise in government funding towards infectious disease diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnosis and testing limited reimbursement scenarios
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of next-generation sequencing-based platform to diagnose respiratory tract infections
      • 5.1.3.2. Expanding number of R&D activities
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory constraints
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Respiratory Infection Diagnostics Market, by Test

  • 6.1. Introduction
  • 6.2. Antigen Detection Assays
  • 6.3. Direct Fluorescent Antibody Tests
  • 6.4. Imaging Tests
    • 6.4.1. CT- Scan
    • 6.4.2. X-ray
  • 6.5. In Vitro Diagnostics (IVD) Tests
  • 6.6. Nucleic Acid Amplification Tests
  • 6.7. Rapid Diagnostic Tests

7. Respiratory Infection Diagnostics Market, by Disease

  • 7.1. Introduction
  • 7.2. Asthma
  • 7.3. Chronic Obstructive Pulmonary Disease
  • 7.4. Coronavirus Infections
  • 7.5. Enterovirus
  • 7.6. Influenza diseases
  • 7.7. Lung Cancer
  • 7.8. Pneumonia
  • 7.9. Tuberculosis
  • 7.10. Whooping Cough (Pertussis)

8. Respiratory Infection Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinical Laboratories
  • 8.3. Hospitals

9. Americas Respiratory Infection Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Respiratory Infection Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Infection Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co. Ltd.
  • 3. Atomo Diagnostics Ltd.
  • 4. Becton, Dickinson and Company
  • 5. Bio-Rad Laboratories Inc.
  • 6. bioMerieux SA
  • 7. BIORON Diagnostics GmbH
  • 8. Cardinal Health Inc.
  • 9. Chembio Diagnostics, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Hologic, Inc.
  • 12. Merck KGaA
  • 13. Meridian Bioscience Inc. by SD Biosensor
  • 14. Quest Diagnostics Incorporated
  • 15. Quidel Corporation

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY INFECTION DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIRECT FLUORESCENT ANTIBODY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CT- SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS (IVD) TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENTEROVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY WHOOPING COUGH (PERTUSSIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023